tiprankstipranks
pc:torag

Toragen Inc

Toragen Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancers caused by the human papillomavirus (HPV). The company is pioneering a first-in-class, oral small molecule inhibitor targeting the HPV E5 protein. Toragen has successfully completed a Phase 1 clinical trial in Stage 4 HPV+ head and neck cancer patients, achieving key safety and efficacy milestones.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$12M
Total Amount Raised$12M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$12M
Latest Funding Amount$12M
Latest Funding RoundConvertible Notes
Latest Funding RoundConvertible Notes
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Convertible Notes
$12.00M

Investors

Investor Name
Funding Round
Convertible Notes
Convertible Notes

Related News and Analysis